Congressional Report Exposes How Chemical Abortion Drug Companies Endanger Mothers. A new Senate GOP investigation led by Sen. Bill Cassidy and the HELP Committee found that the companies making mifepristone, Danco Laboratories, GenBioPro, and Evita Solutions, are not doing the safety oversight the FDA requires, while they make millions selling the abortion pill. These three sponsors could not tell investigators how they actually keep prescribers and pharmacies in compliance with the remaining REMS rules. Those rules require them to make sure doctors can confirm how far along the pregnancy is, rule out a life-threatening ectopic pregnancy, and handle hemorrhage, infection, or the need for surgery or transfusion. The companies said that is not their job, it is the providers’ and pharmacies’ responsibility. Danco has never decertified a single prescriber. It only pulled two pharmacies between late 2024 and 2025. GenBioPro has never decertified any pharmacy. Evita, the newest generic maker, also said compliance is someone else’s problem. The report called it “startling” that none of them could describe any real steps they take against the flood of online prescribers who ignore the rules. Danco’s only product is Mifeprex. Its average yearly revenue is about $16 million (ranging from $1 million to $26 million over 26 years). GenBioPro said roughly 95% of its revenue comes from chemical abortion drugs and that it supplies about two-thirds of the U.S. market. They profit while the safety net they are supposed to run is full of holes. Cassidy: “Abortion drug companies are putting mothers at risk through their failure to properly oversee the prescription and distribution of their products. We are seeing that the explosion in online sales of chemical abortion drugs has opened the door to coercion and abuse of women.” Chemical abortion now accounts for roughly two-thirds of all abortions in America. Independent insurance-claims research covering hundreds of thousands of cases found about 10.93% of women experience a serious adverse event within 45 days, hemorrhage, infection, sepsis, ER visit, or the need for surgery. That is about 22 times higher than the “less than 0.5%” figure the label and FDA have used. Mail-order pills with no in-person exam make ectopic pregnancies, incomplete abortions, and coercion far harder to catch. Tens of thousands of women in states that ban elective abortion still receive these pills by mail every year. The companies collect the money. Women and their unborn children absorb the risk. FDA and these sponsors have a duty to enforce the rules that exist, restore in-person screening, and stop treating this drug like it is no different from any other pill. Mothers deserve protection. Unborn children deserve life. Companies that profit from ending both should not get a free pass on oversight.